About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
CAPR - Capricor Therapeutic...| Previous Close | $5.39 | Open | $5.28 |
| Volume | 862.4K | Market Cap | 110.21M |
| Yield | Last Dividend |
| Exosome Therapeutic Market (COVID-19 Imp... | 10/27/20 |
| This Exosome Therapeutic Market research report makes available state-of-the-art information about the entire market along with the holistic view of t... | |
| The Week Ahead In Biotech: FDA Decisions... | 09/26/20 |
| Biotech stock reversed course last week, dragged lower by the broader market weakness. The week's news flow was headlined by Johnson & Johnson (NYSE: ... | |
| Why Capricor Therapeutics Is Trading Hig... | 08/25/20 |
| Capricor Therapeutics (NASDAQ: CAPR ) shares are trading higher on Tuesday after the company announced the U.S. Food and Drug Administration has accep... | |
| Capricor Therapeutics Reports Second Qua... | 08/06/20 |
| Exosome Platform for COVID-19-Novel Multivalent Exosome mRNA and VLP Vaccine Candidates Underway in Animal Studies--Preclinical Data Shows Positive??? | |
| Capricor Therapeutics to Present Second ... | 07/30/20 |
| Company to Host Conference Call and Webcast, August 6, 2020, at 4:30 p.m. ET | |
| The Daily Biotech Pulse: Merck's Breakth... | 07/29/20 |
| Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 28) Axonics Modulation Technologies Inc (NASDAQ: AXNX ) Capricor Therapeutics Inc (NASDAQ... | |
| Xerostomia Pipeline Research Monitor 202... | 07/24/20 |
| DUBLIN--(BUSINESS WIRE)--The "Xerostomia Pipeline Research Monitor, 2020 - Drugs, Companies, Clinical Trials, R&D Pipeline Updates, Status and Outlook... | |
| Capricor Therapeutics Reports First Quar... | 05/14/20 |
| Duchenne Muscular Dystrophy Program-Final Top-Line 12-month Results from Phase II Randomized, Double-blind, Placebo-controlled HOPE-2- Study Demonstra... | |
| The Daily Biotech Pulse: FDA Nod For Gla... | 04/30/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 29) ??... | |
| Capricor Therapeutics Shares Soar 250% O... | 04/29/20 |
| Capricor Therapeutics Inc.???s (NASDAQ: CAPR) shares soared after data that pointed to a 100 percent survival rate in critical COVID-19 patients ??? | |
| The Daily Biotech Pulse: Roche Obtains F... | 03/13/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) ... | |
| The Daily Biotech Pulse: NY State Endors... | 03/11/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 10)... | |
| The Daily Biotech Pulse: Mesoblast To Te... | 03/10/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 9.) A... | |
| Capricor Therapeutics : SEC Filing - 8-K... | 02/18/20 |
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT ??? | February 18, 2020 | |
| Is Capricor Therapeutics (CAPR) Outperfo... | 02/13/20 |
| Is (CAPR) Outperforming Other Medical Stocks This Year? | |
| The Daily Biotech Pulse: Cassava Gains O... | 12/06/19 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 5) A... | |
| The Daily Biotech Pulse: Amarin Braces F... | 11/14/19 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Nov. 13.) A... | |
| The Daily Biotech Pulse: Merck Goes Shop... | 11/13/19 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 12) ... | |
| Capricor Presents Additional Positive Da... | 10/07/19 |
| Capricor Therapeutics, Inc. (CAPR), a clinical-stage biotechnology company, in its presentation at the 24th Annual International Congress of the World... | |
| Capricor Therapeutics (CAPR) Reports Q2 ... | 08/06/19 |
| Capricor (CAPR) delivered earnings and revenue surprises of 26.25% and 86.36%, respectively, for the quarter ended June 2019. Do the numbers hold clue... | |
| Will Capricor Therapeutics (CAPR) Report... | 08/01/19 |
| Capricor (CAPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with ... | |
| Capicor Therapeutics' stock rockets on h... | 07/15/19 |
| Shares of Capricor Therapeutics Inc. nearly doubled (up 93%) in very active premarket trading Monday, after the biotechnology company announced upbeat... | |
| Capricor Therapeutics, Inc. (CAPR) CEO L... | 05/13/19 |
| Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q1 2019 Earnings Conference Call May 13, 2019, 04:30 PM ET Company Participants AJ Bergmann - CFO Linda Marb... | |
| Capricor Therapeutics (CAPR) Reports Q1 ... | 05/13/19 |
| Capricor (CAPR) delivered earnings and revenue surprises of 27.27% and -42.25%, respectively, for the quarter ended March 2019. Do the numbers hold cl... | |
| Data readout from mid-stage study of Cap... | 05/13/19 |
| No summary available. | |
| Capricor Therapeutics beats by $0.03, mi... | 05/13/19 |
| Capricor Therapeutics (CAPR): Q1 GAAP EPS of -$0.08 beats by $0.03. Revenue of $0.23M (-42.5% Y/Y) misses by $0.2M. Press Release | |
| Capricor Therapeutics, Inc. (CAPR) CEO L... | 03/28/19 |
| Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q4 2018 Earnings Conference Call March 28, 2019 16:30 ET Corporate Participants AJ Bergmann - Chief Financia... | |
| Capricor Therapeutics beats by $0.05, be... | 03/28/19 |
| No summary available. | |
| Date | 2020-11-12 (AMC) | Est. (EPS/Rev.) | ($0.37)/ 210K |
| Actual (EPS/Rev.) | $-0.20/ $16.86 K | EPS (TTM) | 0 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Big Data Zhou | Zhou Academy | 82.00 % | Subscribe |
| Arbitrage Trade Analytics | Royce Wells | 71.00 % | Subscribe |
| Micro | Hao | 36.00 % | Subscribe |
| GOFANG | avinash anantharamu | 0.00 % | Follow |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
